



# ejog

European Journal of

**Obstetrics & Gynecology**  
and Reproductive Biology: 

**Affiliated with**

European Urogynecological  
Association



COLLEGE NATIONAL  
DES GYNÉCOLOGUES  
ET OBSTÉTRICIENS FRANÇAIS



ISSN 2590-1613

## Editorial board

---

### Editor-in-Chief



**Professor Janesh K. Gupta, MD, FRCOG**

Birmingham Women's and Children's NHS Foundation Trust, Birmingham, United Kingdom

Obstetrics, Gynaecology

### Specialty Editors

#### EBCOG



**Dr. Tahir Mahmood**

European Board and College of the Obstetrics and Gynaecology, Brussels, Belgium

Reproductive Medicine, Heavy menstrual bleeding, Obesity, quality improvement in Health

#### Gynecology



**Prof. Dr. Marlies Bongers**

Maastricht University Medical Centre+, Department of Obstetrics and Gynecology, Maastricht, Netherlands



**Gynecological Oncology**

**Maternal-Fetal Medicine**

**Professor Antonio Cano, MD**

University of Valencia, Valencia, Spain

Gynecology, gynecological endocrinology

**Obstetrics**

**Dr. Jane Daniels**

University of Nottingham, Nottingham, United Kingdom

**Professor Justin C. Konje, FMCOG, FWACS, MD, MBA, LLB, FRCOG,**

University of Leicester, Leicester, United Kingdom

Maternal-Fetal Medicine, Recurrent pregnancy loss and Endometriosis

**Dr. Lobna Ouldamer, MD, PhD**

University of Tours, Tours, France



**Dr. Anbukhani Subbian, MBBS DGO DNB MRCOG Fellowship in Gyn Oncology**

Kovai Medical Center and Hospital, Coimbatore, India

Minimal access surgery in Gyn Oncology, Robotic hysterectomy, Sentinel node in Gyn Cancer, Germ cell tumors of ovary, Fertility preservation in Gyn cancers

**Dr. Wiebren Tjalma**

University Hospital Antwerp, Edegem, Belgium

## Professor Tullio Ghi, PhD

University of Parma, Department of Medicine and Surgery, Parma, Italy

Prenatal diagnosis, Fetal growth disorders/Preeclampsia, Labor and delivery, Intrapartum surveillance, Intrapartum ultrasound



## Professor Jim G. Thornton, MD

University of Nottingham, Nottingham, United Kingdom

Obstetrics, randomised trials, labour, birth

## Professor Jack Moodley

University of KwaZulu-Natal College of Health Sciences, Durban, South Africa



## Dr. Helena Strevens

Skåne University Hospital Lund, Lund, Sweden

## Reproductive Biology

## Dr. Mohan S. Kamath

Christian Medical College, Department of Reproductive Medicine and Surgery, Vellore, Tamil Nadu, India



## Professor Ernest H. Y. Ng, MD

The University of Hong Kong, Hong Kong, Hong Kong

Reproductive medicine

## Urogynecology

## Dr. Michele Meschia

University of Milan, Milano, Italy



## Dr. Dudley Robinson, MBBS, MD, FRCOG

King's College London, London, United Kingdom

Urinary Incontinence, Urogenital Prolapse, OAB, Continence Surgery, Oestrogen

## Statistical Editor



## Dr. Eleni Verykoui, PhD

University of Thessaly, Volos, Greece

Biostatistics, Statistical Modelling, Bayesian inference

## Editorial Board Members

## Sir Sabaratnam Arulkumaran, PhD DSc FRCS FRCOG

St George's University of London, London, United Kingdom

Women's Health



## Assoc. Professor Burak Bayraktar, M.D.

Ministry of Health Ankara Etlik City Hospital, Ankara, Turkey

Obstetrics, Gynecology, Maternal Medicine, Fetal Medicine, Perinatal Medicine, Women's Health, Maternal Health



## Dr. Zeev Blumenfeld, MD

Rambam Health Care Campus, Haifa, Israel

## Dr. Sidsel Boie

Randers Regional Hospital, Randers, Denmark

**Dr. Sergio Bracarda, M.D.**

Saint Maria Hospital of Terni, Terni, Italy

**Professor Wood Yee Chan**

The Chinese University of Hong Kong, Faculty of Medicine, Hong Kong, Hong Kong



**Prof. Dr. Pasquapina Ciarmela, PhD**

Polytechnic University of Marche, Ancona, Italy

Gynecology



**Prof. Dr. Giuseppe D'Amato, Medical Degree, specialization in Obstetrics and Gynecology, Physiopathology of Human Reproduction**

University of Tirana, Tirana, Albania

Gynecology, Physiology, Female Reproduction, endocrinology

**Professor Salvatore Dessole**

University of Sassari, Sassari, Italy


**Dr. Gian Carlo Di Renzo**

University of Perugia, Perugia, Italy

**Dr. Joachim W. Dudenhausen, Professor**

Charite University Hospital Berlin, Berlin, Germany

Perinatal Medicine / prematurity / multiple pregnancy / prevention of maternal mortality and stillbirth



**Prof. Dr. Patrícia El Beitune, M.D., Ph.D.**

Federal University of Health Sciences of Porto Alegre, PORTO ALEGRE, Brazil

High risk pregnancy, Ultrasound applications for women's health and maternal-fetal binomial, Clinical research

**Dr. Valter Feyles, MD, MSc, PhD, FRCSC**

Western University, London, Ontario, Canada

**Dr. Thomas Giles Gray, MBChB(Hons) MRCOG MSc MD**

Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, United Kingdom

Patient reported outcome measures, pelvic organ prolapse, urinary incontinence, anal incontinence, sexual dysfunction, medical education

**Professor Andrei G. Gunin, MD, PhD, DrSci**

Chuvash State University named after I N Ulyanov, Cheboksary, Russian Federation

Obstetrics and Gynecology, Oncology, Cell Biology, Aging

**Professor Peter Husslein**

Medical University of Vienna, Department of Obstetrics and Gynaecology, Wien, Austria



**Em. Professor Georgios Iatrakis, PhD**

University of West Attica, Aigaleo, Greece

Gynecologic oncology, Gynecology, Obstetrics, Breast cancer, Prenatal medicine, Pharmacology

**Dr. Hasan Kafali**

Harran University, Şanlıurfa, Turkey



**Prof. Dr. Tulay Okman Kilic, Professor**

Trakya University, Edirne, Turkey

IVF, Obstetrics and Gynecology

**Prof. Dr. Maritta Kühnert**

University of Marburg, Marburg, Germany



**Assist. Prof. Antonio Simone Laganà, MD, PhD**

University of Palermo, Palermo, Italy

Reproductive surgery, Gynecological endocrinology, Assisted Reproduction Technology, Female Infertility, Endometriosis, Gynecology, Gynecological surgery



**Dr. Umberto Leone Roberti Maggiore, MD, PhD**

Foundation IRCCS National Cancer Institute, Milano, Italy

Gynaecology

**Dr. Giancarlo Mari**

Wayne State University, Detroit, Michigan, United States of America

**Professor Gioacchino Mollica**

University of Ferrara, Ferrara, Italy

**Dr. Sven Montan**

Lund University, Lund, Sweden

**Professor Karsten Münstedt**

Justus Liebig University Giessen, Gießen, Germany



**Professor Jacky Nizard**

University Hospitals Pitie Salpetriere- Charles Foix, Paris, France

**Dr. Colm O'Herlihy**

University College Dublin School of Medicine, Dublin, Ireland

**Dr. Miriam O'Kane, N/A**

Cambridge, United Kingdom

Urogynaecology

**Professor Benjamin Piura**

Ben-Gurion University of the Negev, Be'er Sheva, Israel



**Dr. Angie Marie Rantell, PhD, ALNP**

King's College Hospital, London, United Kingdom

female sexual dysfunction, female lower urinary tract dysfunction, pelvic organ prolapse, conservative management, pelvic floor dysfunction, urodynamics, management of over active bladder



**Dr. Akanksha Sood, MBBS, MS OBGY, DNB, MRCOG, FACOG**

Manchester University NHS Foundation Trust, Manchester, United Kingdom

Fertility, Assisted Conception, IVF, Benign gynaecology

**Professor Thomas Strowitzki**

Heidelberg University, Heidelberg, Germany



**Dr. Andrea Tinelli, MD, Prof, PhD**

Ceriscal Centro Ricerca Clinica Salentino, Scorrano, Italy

Gynecological surgery, Uterine fibroids, Obstetric surgery, Endometriosis, Gynecological Oncology



**Prof. Dr. Adi Y. Weintraub, MD**

Soroka Medical Center, Be'er Sheva, Israel

urinary incontinence, pelvic organ prolapse, obstetric anal sphincter injuries OASIS, medical education

Review article ● *Open access*

## Intramural ectopic pregnancy: An individual patient data systematic review

Carnot N. Ntafam, ItunuOluwa Sanusi-Musa, Robert D. Harris  
Article 100272



[View PDF](#)

Article preview

Review article ● *Open access*

## About half of Ethiopian midwifery professionals reported being dissatisfied with their jobs: A systematic review and meta-analysis

Dagne Deresa Dinagde, Shambel Negesa marami, Gizu Tola Feyisa, Bekem Dibaba Degefa  
Article 100277



[View PDF](#)

Article preview

Review article ● *Open access*

## An uncommon case of metastatic undifferentiated pleomorphic soft tissue sarcoma during pregnancy: Literature review and case report

Valentina Sala, Giuliana Di Simone, Chiara Lubrano, Aida Quarenghi, ... Irene Cetin  
Article 100278



[View PDF](#)

Article preview

Review article ● *Open access*

## A review of the pharmacology, clinical outcomes, and real-world effectiveness, safety, and non-contraceptive effects of NOMAC/E2

Franca Fruzzetti, Rogerio Bonassi Machado, Iñaki Lete, Amisha Patel, Mitra Boolell  
Article 100283



[View PDF](#)

Article preview

Review article ● *Open access*

## Differences in cervical length during the second trimester among normal weight, overweight and obese women: A systematic review and meta-analysis

Michail Panagiotopoulos, Vasilios Pergialiotis, Konstantina Trimmi, Antonia Varthaliti, ... Georgios Daskalakis  
Article 100291



[View PDF](#)

Article preview

## Gynaecology

---

Research article ● *Open access*

## Association between witnessing domestic violence against the mother in childhood and intimate partner violence in adulthood: A population-based analysis of Peru

Guido Bendezu-Quispe, Daniel Fernandez-Guzman, Brenda Caira-Chuquineyra, Diego Urrunaga-Pastor, ... Jaime Rosales-Rimache  
Article 100275

[View PDF](#)[Article preview](#)

Research article ● *Open access*

## Methotrexate as the first-line treatment of unruptured tubular ectopic pregnancies with high initial human chorionic gonadotropin levels: A retrospective cohort

Fatemeh Keikha, Shireen Shams Ardekani, Mohammadamin Parsaei, Nikan Zargarzadeh, ... Azadeh Tarafdari  
Article 100286

[View PDF](#)[Article preview](#)

Research article ● *Open access*

## Female sexuality across the menopausal age group: A cross sectional study

Rajlaxmi Mundhra, Anupama Bahadur, Kavita Khoiwal, Mukesh Kumar, ... Jaya Chaturvedi  
Article 100287

[View PDF](#)[Article preview](#)

### Gynaecology: Oncology

---

Research article ● *Open access*

## The effect of pentoxifylline and different types of exercise training on coagulation factors in a rat endometriosis model

Zahra Salehpoor, Mohamad Rezapourmoghadam, Nader Tanideh, Maryam Koushkie Jahromi  
Article 100292

[View PDF](#)[Article preview](#)

Research article ● *Open access*

## Correlation between estrogen receptor and programmed death ligand-1 in type I endometrial cancer

Setyo Teguh Waluyo, Brahmana Askandar Tjokroprawiro, Anny Setijo Rahaju  
Article 100293

[View PDF](#)[Article preview](#)

### Obstetrics and Maternal Fetal Medicine

---

Research article ● *Open access*





## Correlation between estrogen receptor and programmed death ligand-1 in type I endometrial cancer

Setyo Teguh Waluyo<sup>a</sup>, Brahmana Askandar Tjokropawiro<sup>b,\*</sup>, Anny Setijo Rahaju<sup>c</sup>

<sup>a</sup> *Subspecialist Education Program, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Dr. Soetomo General Academic Hospital, Medical Faculty –Universitas Airlangga, Surabaya, Indonesia*

<sup>b</sup> *Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Faculty of Medicine, Universitas Airlangga/Dr. Soetomo General Academic Hospital, Surabaya, Indonesia*

<sup>c</sup> *Department of Anatomical Pathology, Faculty of Medicine, Universitas Airlangga/Dr. Soetomo General Academic Hospital/ Universitas Airlangga Hospital, Surabaya, Indonesia*

### ARTICLE INFO

#### Keywords:

Estrogen receptor  
Endometrial cancer, programmed death ligand-1

### ABSTRACT

**Objective:** To determine the effect of estrogen receptor (ER) on programmed death-ligand 1 (PD-L1) expression in type I endometrial cancer (EC).

**Material and Methods:** This retrospective study included 85 patients with type I EC who underwent surgery at Dr. Soetomo Hospital between 2018 and 2022. A random sampling technique was employed. Immunohistochemistry (IHC) with ER and PD-L1 antibodies was performed on all samples. In this study, ER expression served as the independent variable, while PD-L1 expression was considered the dependent variable. Data analysis was performed using Spearman's rank correlation coefficient test.

**Results:** Out of the 85 patients with type I EC, 58 (68.2%) exhibited positive and 27 (31.8%) exhibited negative ER expression. Meanwhile positive PD-L1 expression was seen in 67 (78.8%) and 18 (21.2%) exhibited negative PD-L1 expression. The study revealed a strong negative correlation between ER and PD-L1 expression in EC (rho value = -0.886, p-value = 0.0001).

**Conclusion:** ER downregulates PD-L1 in type I EC. The findings of this study can be used as reference data and as the basis for further research, especially investigations of the prognostic and immunotherapeutic value of ER and PD-L1 expression in type I EC.

### 1. Introduction

Endometrial cancer encompasses a group of primary malignant epithelial tumors that originate in the inner surface of the uterine wall, known as the endometrium. The most common causes of EC include a family history of the disease, menstrual abnormalities, infertility, exposure to estrogen, the use of hormonal drugs, obesity, diabetes, and a high body mass index (BMI) [1]. Notably, the incidence of endometrial cancer is on the rise, particularly in developed countries, like the United States [2]. In Korea, the increasing incidence can be attributed to shifting lifestyles and environmental factors [3–5]. In Indonesia, EC is now the third leading cause of cancer-related death among women [6]. Projections suggest that the incidence of EC may increase by 20.3% by 2025, with a corresponding 17.4% rise in the number of deaths

compared to 2018 [5].

Endometrial cancer is classified into two main histological types: I and II. Type I, which accounts for approximately 85% of cases of EC, is often linked to estrogen exposure. It is characterized by well-differentiated endometrioid histology, hormone receptor expression, and diploidy. Notably, it tends to be diagnosed at an early stage and carries a good prognosis. In contrast, Type II endometrial cancer is associated with advanced disease stages, non-endometrioid histological characteristics (serous endometrial carcinoma, clear cell carcinoma, or mixed carcinoma), high histological grade, aneuploidy, lack of hormone receptors, frequent TP53 mutations, and poor prognosis [7–9]. Recent advancements in genome analysis technology have revealed genomic anomalies within EC. Additionally, integrated genomic analyses have identified molecular subgroups that align with prognosis. The most

\* Correspondence to: Department of Obstetrics and Gynecology, Faculty of Medicine, Universitas Airlangga/ Dr. Soetomo General Academic Hospital, Prof. Dr. Moestopo 6-8, Surabaya 60286, Indonesia.

E-mail address: [brahmanaaskandar@fk.unair.ac.id](mailto:brahmanaaskandar@fk.unair.ac.id) (B.A. Tjokropawiro).

<https://doi.org/10.1016/j.eurox.2024.100293>

Received 4 October 2023; Received in revised form 25 January 2024; Accepted 16 February 2024

Available online 20 February 2024

2590-1613/© 2024 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC license (<http://creativecommons.org/licenses/by-nc/4.0/>).



notable approach of integrating molecular characteristics with EC classification by the Cancer Genome Atlas (TCGA) has resolved the numerous limitations in risk stratification [1]. The TCGA classifies EC into four distinct genomic categories that are Poymerase e mutation (POLE-Mutant), Mismatch Repair Deficiency (MMRd), P53 wild type / Non Specified Molecular Profile (NSMP), P53 high copy (P53-abn) [10].

Diverse biological abnormal changes in pathways have been discerned in EC cells. This has prompted the active development of novel therapeutic drugs and biomarkers, including immunomodulation inhibitors targeting programmed cell death protein 1 (PD-1) or PD-L1, to address these anomalies [1]. The landscape of cancer therapy has shifted with the advent of precision therapy and ongoing EC research. Immunotherapy, particularly is the use of a PD-1 inhibitors can be influenced by the expression of its ligand, PD-1 inhibitor as a potential treatment for EC the recommendations of the National Comprehensive Cancer Network (NCCN). Elevated expression of PD-L1 may be an immune response to tumor invasion.

Previous studies examining the correlation between ER and PD-L1 in breast cancer patients [11] have revealed that ER downregulates PD-L1 expression through interleukin-17 (IL-17). Based on these findings, we have designed a study to determine the effect of the ER on PD-L1 expression in type I EC wich is also estrogen dependent cancer, while also exploring the potential utility of ER status in the use of inhibitor immunotherapy in EC.

## 2. Materials and methods

This was a retrospective, cross-sectional histopathological study conducted using paraffin blocks of tissue obtained from patients who received treatment for type 1 EC at Dr. Soetomo Hospital Surabaya, Indonesia, between January 2018 to December 2022. We found total sample of 115 patient who meet inclusion and exclusion criteria, and 85 patient samples were collected through random sampling to reduce of bias. The inclusion criteria stipulated that patients had type I EC and underwent surgery at Dr. Soetomo Hospital, Surabaya, from 2018 to 2022. Paraffin blocks containing representative tumor masses were available at the Anatomical Pathology Laboratory of Dr. Soetomo Hospital. The exclusion criteria involved cases of type I EC that had malignancy in other organs. In this study, ER expression in type I EC served as the independent variable, and PD-L1 expression in type I EC was the dependent variable. Data analysis was performed using Spearman's rank correlation coefficient test.

Paraffin blocks of tissues from patients with type I EC were collected from the anatomical pathology laboratory to obtain immunohistochemical data for ER and PD-L1 antibodies. ER expression was determined, by staining endometrial tissue paraffin blocks with Biocare Medical ER™ (SP1) ER antibodies using the LSAB II method and fixation with 10% neutral buffered formalin (NFB). For PD-L1 expression analysis, immunohistochemical staining was performed on endometrial tissue paraffin blocks using the PD-L1 GeneAb™ antibody from GenomeMe™ clone IHC411. It was derived from the membrane or cytoplasm of rabbit monoclonal cells using the LSAB II method and fixation with 10% NFB. The methodology was approved by the Research Ethics Committee of Dr. Soetomo Hospital Surabaya, Indonesia.

## 3. Results

A total of 85 patient samples were collected. Results showed that there were 41 patients (48.2%) in the age group < 55 years and 44 patients (51.8%) in the age group > 55 years. The BMI group had 6 patients (7.1%) in the underweight group, 36 patients (42.4%) in the normal-weight group, 14 patients (16.5%) in the overweight group, 23 patients (27.1%) in the obesity class I group, and 6 patients (7.1%) in the obesity class II group. In the menopausal status group, 39 patients (45.9%) were in the premenopausal group and 46 patients (54.1%) in the menopausal group. The disease stage group had 45 patients (52.9%)

in the early stage group and 40 patients (47.1%) in the advanced stage group. The cell differentiation group, 54 patients (63.5%) in the low-grade group, and 31 patients (36.5%) in the high-grade group. The nodal metastasis group had 76 patients (89.4%) in the group with no nodal metastasis and 9 patients (10.6%) in the group with nodal metastatic. In the LVSI group, 59 patients (69.4%) were found in the group with no LVSI and 26 patients (30.6%) in the group with LVSI. The myometrial invasion group had 22 patients (25.9%) in the group with < 1/2 myometrial invasion, and 63 patients (74.1%) in the group with ≥ 1/2 myometrial invasion. The adjuvant therapy group had 19 patients (22.4%) in the group that was not given adjuvant therapy, and 66 patients (77.6%) in the group that was given adjuvant therapy. Table 1.

### 3.1. Positive ER and PD-L1 expression in type I EC

Among the 85 patients with type I EC, 58 (68.2%) exhibited positive ER expression, while 27 (31.8%) were ER-negative. Moreover, out of the

**Table 1**  
Sample Demographic.

Characteristics	Frequency	Percentage
Age	Mean: 53.42	
<55 years	41	48.2 %
≥55 years	44	51.8 %
Sum	85	100 %
BMI		
Underweight	6	7.1 %
Normoweight	36	42.4 %
Overweight	14	16.5 %
Obesity class 1	23	27.1 %
Obesity class 2	6	7.1 %
Obesity class 3	0	0 %
Sum	85	100 %
Menopause status		
Yes	46	54.1 %
No	39	45.9 %
Sum	85	100 %
Cancer Stage		
Early Stage (I, II)	45	52.9 %
Advanced Stage (III, IV)	40	47.1 %
Sum	85	100 %
Myometrium Invasion:		
<1/2 myometrium	22	25.9 %
≥1/2 myometrium	63	74.1 %
Sum	85	100 %
Nodal metastasis:		
Yes	9	10.6 %
No	76	89.4 %
Sum	85	100 %
Cell Differentiation ( <i>tumor grade</i> ):		
Low grade (I and II)	54	63.5 %
High grade (III and IV)	31	36.5 %
Sum	85	100 %
LVSI:		
Yes	26	30.6 %
No	59	69.4 %
Sum	85	100 %
Adjuvant Therapy:		
Yes	66	77.6 %
No	19	22.4 %
Sum	85	100 %
Expression of ER:		
Positive	58	68.2 %
Negative	27	31.8 %
Sum	85	100 %
Expression of PD-L1:		
Positive	67	21.2%
Negative	18	21.2 %
Sum	85	100 %

85 patients with type I EC, 67 (78.8%) displayed positive PD-L1 expression, whereas 18 (21.2%) were PD-L1-negative. (Fig. 1).

### 3.2. Correlation between ER and PD-L1 expression in type I EC

Coefficient correlation analysis using Spearman's rank was conducted to test the correlation between ER and PD-L1 expression. The results indicated a statistically strong negative correlation between ER and PD-L1 expression in type I EC, with a rho value of  $-0.886$  and a p-value of  $0.0001$ . (Fig. 2) Based on this result we assume that ER expression downregulates PD-L1 in type I EC.

## 4. Discussion

The result of the present study found that ER expression was positive in 68.2% of the cases of type 1 endometrial cancer. This finding is similar to the results of the study by Wang et al. in 2007, in which ER positivity was found in 59.8% of cases of endometrial cancer in a study population in China [12]. The results of the present study also indicated that PD-L1 expression was positive in 78.8% of the cases of type 1 endometrial cancer. A meta-analysis of 11 studies revealed that PD-L1 expression in endometrial cancer is quite diverse. The results of our study are similar to those of Zhang et al. (2020), in which PD-L1 positivity was found in 70.14% of endometrial cancer cases in a study population in Japan [13]. Engerud et al. also reported PD-L1 positivity of 63% in primary tumors [14]. Through gene expression analysis, researchers have shown that PD-L1 is upregulated in PD-1-positive tumor cells [15]. In contrast, Pasenan et al., in a 2019 study of patients in Finland, reported a PD-L1 positivity of only 8.58%. This difference is likely due to racial differences in the research sample, but whether there is a relationship between PD-L1 expression and race requires further research [16].

### 4.1. Role of PD-1/PD-L1 in immunotherapy for EC

The PD-1/PD-L1 pathway plays a crucial role in the immune escape mechanism and growth of cancer cells in EC. Clinical trials investigating efficacy of PD-1/PD-L1 inhibitor have shown promising results in EC [17]. PD-1 inhibitors as a potential treatment for EC has been recommended by NCCN. Immunotherapy, particularly is the use of a PD-1 inhibitors can be influenced by the expression of its ligand, Elevated expression of PD-L1 may be an immune response to tumor invasion. Recent investigations have unveiled that anti-PD-1/PD-L1 first line therapy yields response rates varying between 20% and 65% in




Fig. 1. Negative expression of ER in the cell nucleus (A). Strong expression of PD-L1 in the cell membrane (B). Strong expression of ER on the cell nucleus (C). Negative expression of PD-L1 on the cell membrane (D). There is a negative correlation between ER expression and PD-L1 expression. (magnification: 400x, scale bar: 50  $\mu$ m).




Fig. 2. Correlation Coefficient Curve of ER and PD-L1 Expression.

PD-L1-positive tumours in various cancers, including EC [17]. Conversely, tumours lacking PD-L1 expression exhibit response rates ranging from 0% to 17% across diverse tumour types [18]. The significance of PD-L1 expression within the tumour microenvironment is recognised as a pivotal biomarker for identifying individuals who are more likely to benefit therapeutically from immunotherapy.

### 4.2. PD-L1 regulation by estrogen pathway in cancer

Estrogens downregulate PD-L1 expression in EC and correlates with ER-negative status in EC [11] Estrogen mechanisms modifying PD-L1 seem to be complex and may depend on several factors such as cancer type, histology, tumor mutational burden (TMB), ER isoforms, Aromatase expression and estrogen levels. This relationship needs to be explored since E2 pathway blocking could improve immunotherapy in some cancers [19].

The results of the present study showed a strong negative correlation between ER and PD-L1 expression in type 1 endometrial cancer (rho value =  $-0.886$  and p-value =  $0.0001$ ). This negative correlation may be because ER downregulates PD-L1 by activated estradiol to recruit a repressor of estrogen receptor activity (REA) and form the ER/REA complex, which binds the estrogen receptor element (ERE) on the retinoic acid receptor-related orphan nuclear receptor gamma (ROR $\gamma$ T) promoter. As a result of the inhibition of ROR $\gamma$ T, Th17 cell differentiation, and infiltration are impeded, thereby weakening IL-17 signal transduction intensity and decreasing PD-L1 expression [11,20].

ER deficiency causes increased infiltration of Th17 cells, which upregulate IL-17 signal transduction. IL-17 binds its receptor IL-17R in the tumor microenvironment, which activates NF- $\kappa$ B signaling and NF- $\kappa$ B translocation to promote PD-L1 translation and increase expression on the cell membrane. The synergy of IL-17, IFN $\gamma$ , and TNF $\alpha$  promotes PD-L1 expression [11,20]. After translation, NfKB regulates and maintains PD-L1 expression by inducing the transcription of the COPS5 gene, which deubiquitinates PD-L1 protein to stabilize PD-L1 on the cell membrane [11,20] ( Fig. 3).

To the best of our knowledge, the present study is the first in which the correlation between ER and PD-L1 expression has been confirmed in type I EC. New therapies for EC therapy are rapidly developing. One of these novel therapies is the use of PD-1 inhibitor, the effectiveness of this approach has been demonstrated by measuring the degree of ligand (PD-L1) expression in immune cells and tumor cells. Based on these results we assume that ER status can predict the response of PD-1 inhibitor in EC, and adding anti-estrogen could potentially improve the response of PD-1 inhibitor in EC. The limitations of this study, insofar as it was a retrospective study and did not address all the possible factors that may influence PD-L1 expression. Notwithstanding these limitations, the findings we report here can serve as reference data or the base for further




Fig. 3. PD-L1 regulation by estrogen pathway in cancer

research into the potential of ER and PD-L1 as prognostic and improve the efficacy of immunotherapy in EC.

## 5. Conclusion

ER downregulates PD-L1 in type 1 EC. The findings of this study can be used as reference data and as the basis for further research, especially investigations of the prognostic and immunotherapeutic value of ER and PD-L1 expression in type 1 EC. Further research is needed to determine the role of ER and PD-L1 expression in disease outcomes, recurrence rates and survival rates of patients with type 1 EC.

## Funding

The authors declare no financial support for this study.

## CRediT authorship contribution statement

**Setyo Teguh Waluyo:** Conceptualization, Data curation, Formal analysis, Writing – original draft. **Brahmana Askandar Tjokropriawiro:** Formal analysis, Supervision, Writing – original draft. **Anny Setijo Rahaju:** Data curation, Writing – review & editing, Methodology.

## Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this article.

## References

- Mamat @ Yusof MN, Chew KT, Kampan NC, et al. Expression of PD-1 and PD-L1 in endometrial cancer: molecular and clinical significance. *Int J Mol Sci* 2023;24. <https://doi.org/10.3390/IJMS242015233>. Epub ahead of print 1 October.
- Siegel RL, Miller KD, Fuchs HE, et al. *Cancer statistics, 2021*. *CA Cancer J Clin* 2021;71:7–33.
- Lee JY, Kim K, Lee TS, et al. Controversies in the management of endometrial cancer: a survey of the Korean Gynecologic Oncology Group. *J Gynecol Oncol* 2015;26:277.
- Lim MC, Won YJ, Ko MJ, et al. Incidence of cervical, endometrial, and ovarian cancer in Korea during 1999–2015. *J Gynecol Oncol* 2019;30. <https://doi.org/10.3802/JGO.2019.30.E38>. Epub ahead of print 1 January.
- Bray F, Ferlay J, Soerjomataram I, et al. *Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries*. *CA Cancer J Clin* 2018;68:394–424.
- Gondhowiardjo S, Christina N, Ganapati NPD, et al. Five-year cancer epidemiology at the national referral hospital: hospital-based cancer registry data in Indonesia. *JCO Glob Oncol* 2021;7:190–203.
- Rabinovich A. Neo-adjuvant chemotherapy for advanced stage endometrial carcinoma: a glimmer of hope in select patients. *Arch Gynecol Obstet* 2016;293:47–53.
- Lee YC, Lheureux S, Oza AM. Treatment strategies for endometrial cancer: current practice and perspective. *Curr Opin Obstet Gynecol* 2017;29:47–58.
- Morice P, Leary A, Creutzberg C, et al. *Endometrial cancer*. *Lancet (Lond, Engl)* 2016;387:1094–108.
- Kommos S, McConechy MK, Kommos F, et al. Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series. *Ann Oncol J Eur Soc Med Oncol* 2018;29:1180–8.
- Shuai C, Yang X, Pan H, et al. Estrogen receptor downregulates expression of PD-1/PD-L1 and infiltration of CD8<sup>+</sup> T cells by inhibiting IL-17 signaling transduction in breast cancer. *Front Oncol* 2020;10. <https://doi.org/10.3389/FONC.2020.582863/FULL>. Epub ahead of print 25 September.
- Wang C, Tran DA, Fu MZ, et al. Estrogen receptor, progesterone receptor, and HER2 receptor markers in endometrial cancer. *J Cancer* 2020;11:1693.
- Zhang S, Minaguchi T, Xu C, et al. PD-L1 and CD4 are independent prognostic factors for overall survival in endometrial carcinomas. *BMC Cancer* 2020;20:1–12.
- Engerud H, Berg HF, Myrvold M, et al. High degree of heterogeneity of PD-L1 and PD-1 from primary to metastatic endometrial cancer. *Gynecol Oncol* 2020;157:260–7.
- Mamat @ Yusof MN, Chew KT, Kampan N, et al. PD-L1 Expression in endometrial cancer and its association with clinicopathological features: a systematic review and meta-analysis. *Cancers* 2022;14. <https://doi.org/10.3390/CANCERS14163911>. Epub ahead of print 1 August (Basel).
- Pasanen A, Ahvenainen T, Pellinen T, et al. PD-L1 Expression in Endometrial Carcinoma Cells and Intratumoral Immune Cells: Differences Across Histologic and TCGA-based Molecular Subgroups. *Am J Surg Pathol* 2020;44:174–81.
- Mamat @ Yusof MN, Chew KT, Hafizz AMHA, et al. Efficacy and safety of PD-1/PD-L1 inhibitor as single-agent immunotherapy in endometrial cancer: a systematic review and meta-analysis. *Cancers* 2023;15. <https://doi.org/10.3390/CANCERS15164032>. Epub ahead of print 1 August (Basel).

- [18] Patel SP, Kurzrock R. PD-L1 expression as a predictive biomarker in cancer immunotherapy. *Mol Cancer Ther* 2015;14:847–56.
- [19] Rodriguez-Lara V, Giovanni SC, Avila-Costa MR, et al. Role of sex and sex hormones in PD-L1 expression in NSCLC: clinical and therapeutic implications. *Front Oncol* 2023;13. <https://doi.org/10.3389/FONC.2023.1210297> (Epub ahead of print).
- [20] Betzler AC, Theodoraki MN, Schuler PJ, et al. NF-κB and its role in checkpoint control. *Int J Mol Sci* 2020;21. <https://doi.org/10.3390/IJMS21113949>. Epub ahead of print 1 June.

# Source details

## European Journal of Obstetrics and Gynecology and Reproductive Biology: X

Open Access ⓘ

Scopus coverage years: from 2019 to Present

Publisher: Elsevier

ISSN: 2590-1613 E-ISSN: 2590-1613

Subject area: Medicine: Reproductive Medicine Medicine: Obstetrics and Gynecology

Source type: Journal

CiteScore 2022  
**4.7** ⓘ

SJR 2022  
**0.709** ⓘ

SNIP 2022  
**1.261** ⓘ

[View all documents >](#)

[Set document alert](#)

[Save to source list](#)

[CiteScore](#) [CiteScore rank & trend](#) [Scopus content coverage](#)

### Improved CiteScore methodology

CiteScore 2022 counts the citations received in 2019-2022 to articles, reviews, conference papers, book chapters and data papers published in 2019-2022, and divides this by the number of publications published in 2019-2022. [Learn more >](#)

CiteScore 2022 ⌵

$$4.7 = \frac{631 \text{ Citations 2019 - 2022}}{134 \text{ Documents 2019 - 2022}}$$

Calculated on 05 May, 2023

CiteScoreTracker 2023 ⓘ

$$2.2 = \frac{301 \text{ Citations to date}}{137 \text{ Documents to date}}$$



Last updated on 05 April, 2024 • Updated monthly

### CiteScore rank 2022 ⓘ

Category	Rank	Percentile
Medicine		
Reproductive Medicine	#19/80	76th
Medicine		
Obstetrics and Gynecology	#47/197	76th

[View CiteScore methodology >](#) [CiteScore FAQ >](#) [Add CiteScore to your site ↗](#)












# European Journal of Obstetrics and Gynecology and Reproductive Biology: X

<b>COUNTRY</b>  Ireland  Universities and research institutions in Ireland  Media Ranking in Ireland	<b>SUBJECT AREA AND CATEGORY</b>  Medicine Obstetrics and Gynecology Reproductive Medicine	<b>PUBLISHER</b>  Elsevier Ireland Ltd	<b>H-INDEX</b>  <b>15</b>
<b>PUBLICATION TYPE</b>  Journals	<b>ISSN</b>  25901613	<b>COVERAGE</b>  2019-2023	<b>INFORMATION</b>  <a href="#">Homepage</a> <a href="#">How to publish in this journal</a> <a href="mailto:euro@elsevier.com">euro@elsevier.com</a>

## SCOPE

European Journal of Obstetrics & Gynecology and Reproductive Biology and European Journal of Obstetrics & Gynecology and Reproductive Biology: X have the same aims and scope. A unified editorial team manages rigorous peer-review for both titles using the same submission system. The author's choice of journal is blinded to referees, ensuring the editorial process is identical. The European Journal of Obstetrics & Gynecology and Reproductive Biology is the leading general clinical journal covering the continent. It publishes peer reviewed original research articles, as well as a wide range of news, book reviews, biographical, historical and educational articles and a lively correspondence section. Fields covered include obstetrics, prenatal diagnosis, maternal-fetal medicine, perinatology, general gynecology, gynecologic oncology, uro-gynecology, reproductive medicine, infertility, reproductive endocrinology, sexual medicine and reproductive ethics. The European Journal of Obstetrics & Gynecology and Reproductive Biology provides a forum for scientific and clinical professional communication in obstetrics and gynecology throughout Europe and the





European Journal of Obstetrics and Gynecology...

Q2  
Obstetrics and Gynecology  
best quartile

SJR 2023  
0.53

powered by scimagojr.com

Show this widget in your own website

Just copy the code below and paste within your html code:

<a href="https://www.scima

**SCImago Graphica**

Explore, visually





**RUMAH SAKIT UMUM DAERAH  
Dr. SOETOMO**



**KOMITE ETIK PENELITIAN KESEHATAN  
RSUD Dr. SOETOMO SURABAYA**

**KETERANGAN KELAIKAN ETIK  
(" ETHICAL CLEARANCE ")**

**0606/KEPK/II/2023**

**KOMITE ETIK RSUD Dr. SOETOMO SURABAYA TELAH MEMPELAJARI  
SECARA SEKSAMA RANCANGAN PENELITIAN YANG DIUSULKAN, MAKA  
DENGAN INI MENYATAKAN BAHWA PENELITIAN DENGAN JUDUL :**

**" Hubungan Ekspresi Estrogen Receptor dengan Programmed Death Ligand-1 pada  
Kanker Endometrium Tipe I "**

**PENELITI UTAMA : Dr. Brahmana Askanda Tjokroprawiro, dr., Sp.OG (K)**

**PENELITI LAIN : 1. Dr. Anny Setijo Rahaju, dr., Sp.PA (K)  
2. Setyo Teguh Waluyo, dr., Sp.OG**

**UNIT / LEMBAGA / TEMPAT PENELITIAN : RSUD Dr. Soetomo**

**DINYATAKAN LAIK ETIK**

**Berlaku dari : 27/02/2023 s.d 27/02/2024  
Surabaya, 27 February 2023**

**KETUA**

**(Prof. Dr. Hendy Hendarto, dr., SpOG (K))  
NIP. 19610817 201601 6 101**

***\*) Sertifikat ini dinyatakan sah apabila telah mendapatkan stempel asli dari Komite Etik  
Penelitian Kesehatan***